Rate of reversal of hypercalcaemia and hypercalciuria induced by vitamin D and its 1alpha-hydroxylated derivatives.
作者信息
Kanis J A, Russell R G
出版信息
Br Med J. 1977 Jan 8;1(6053):78-81. doi: 10.1136/bmj.1.6053.78.
Abstract
The rate of reversal of hypercalcaemia or hypercalciuria induced by calciferol, dihydrotachysterol, 1-alpha-hydroxycholecalciferol (1-alpha-OHD3), or 1-alpha, 25-dihydroxycholecalciferol (1-alpha, 25-(OH)2D3) was measured in three normal subjects, two patients with osteoporosis, and 14 patients with disorders resistant to vitamin D. The half time for reversal after stopping 1-alpha, 25 (OH)2D3 was less than that after stopping 1-alpha-OHD3, calciferol, or dihydrotachysterol. The differences observed were independent of the dose given or length of treatment. When 1-alpha-OHD3 or 1-alpha-25-(OH)2D3 was stopped patients with vitamin D resistant states (hypoparathyroidism, renal tubular hypophosphataemia, or chronic renal failure) showed less rapid reversal of hypercalcaemia and hypercalciuria than did normal subjects. These studies show one potential advantage of 1-alpha-25-(OH)2D3 over vitamin D, and possibly over 1-alpha-OHD3, in the management of vitamin D resistant states.
摘要
相似文献
1
Rate of reversal of hypercalcaemia and hypercalciuria induced by vitamin D and its 1alpha-hydroxylated derivatives.
Br Med J. 1977 Jan 8;1(6053):78-81. doi: 10.1136/bmj.1.6053.78.
2
Deterioration of renal function during treatment of chronic renal failure with 1,25-dihydroxycholecalciferol.
Lancet. 1978 Sep 30;2(8092 Pt 1):700-3. doi: 10.1016/s0140-6736(78)92702-2.
3
Long-term treatment of postmenopausal osteoporosis with active vitamin D3, 1-alpha-hydroxycholecalciferol (1 alpha-OHD3) and 1, 24 Dihydroxycholecalciferol (1, 24(OH)2D3).
Endocrinol Jpn. 1985 Apr;32(2):305-15. doi: 10.1507/endocrj1954.32.305.
4
Inhibition by calcitonin of hypercalcaemia induced by 1,25-dihydroxycholecalciferol.
J Endocrinol. 1980 Apr;85(1):63-7. doi: 10.1677/joe.0.0850063.
5
Effects of vitamin D and its metabolites on calcium transport in the diabetic rat.
Endocrinology. 1976 Sep;99(3):793-9. doi: 10.1210/endo-99-3-793.
6
Radioligand receptor assay for 25-hydroxyvitamin D2/D3 and 1 alpha, 25-dihydroxyvitamin D2/D3.
J Clin Invest. 1976 Jul;58(1):61-70. doi: 10.1172/JCI108459.
7
8
Some characteristics of cytosol binding protein for 1alpha,25-dihydroxycholecalciferol and 25-hydroxycholecalciferol in rat intestinal mucosa.
J Nutr Sci Vitaminol (Tokyo). 1977;23(3):187-200. doi: 10.3177/jnsv.23.187.
9
Use of 1,25(OH)2-vitamin D3 in prevention of renal osteodystrophy: preliminary observations.
Contrib Nephrol. 1980;18:147-51. doi: 10.1159/000403282.
10
Vitamin D metabolism in hypoparathyroidism.
J Clin Endocrinol Metab. 1980 Sep;51(3):606-10. doi: 10.1210/jcem-51-3-606.
引用本文的文献
1
From Psychiatry to Neurology and Endocrinology: A Case of Hypoparathyroidism.
Cureus. 2020 Sep 26;12(9):e10666. doi: 10.7759/cureus.10666.
2
Five-year Estimated Glomerular Filtration Rate in Patients With Hypoparathyroidism Treated With and Without rhPTH(1-84).
J Clin Endocrinol Metab. 2020 Oct 1;105(10):e3557-65. doi: 10.1210/clinem/dgaa490.
3
Diagnosis and treatment of hypoparathyroidism: a position statement from the Brazilian Society of Endocrinology and Metabolism.
Arch Endocrinol Metab. 2018 Feb;62(1):106-124. doi: 10.20945/2359-3997000000015.
4
Current treatment of hypoparathyroidism: Theory versus reality waiting guidelines for children and adolescents.
Acta Biomed. 2018 Mar 27;89(1):122-131. doi: 10.23750/abm.v89i1.7118.
5
Hypoparathyroidism: Less Severe Hypocalcemia With Treatment With Vitamin D2 Compared With Calcitriol.
J Clin Endocrinol Metab. 2017 May 1;102(5):1505-1510. doi: 10.1210/jc.2016-3712.
6
Management of Hypoparathyroidism: Present and Future.
J Clin Endocrinol Metab. 2016 Jun;101(6):2313-24. doi: 10.1210/jc.2015-3910. Epub 2016 Mar 3.
7
Reversible vascular calcifications associated with hypervitaminosis D.
J Nephrol. 2016 Feb;29(1):129-31. doi: 10.1007/s40620-015-0228-7. Epub 2015 Aug 30.
8
Synthetic human parathyroid hormone 1-34 replacement therapy: a randomized crossover trial comparing pump versus injections in the treatment of chronic hypoparathyroidism.
J Clin Endocrinol Metab. 2012 Feb;97(2):391-9. doi: 10.1210/jc.2011-1908. Epub 2011 Nov 16.
9
Hypoparathyroidism in the adult: epidemiology, diagnosis, pathophysiology, target-organ involvement, treatment, and challenges for future research.
J Bone Miner Res. 2011 Oct;26(10):2317-37. doi: 10.1002/jbmr.483.
10
Vitamin D and analogues in renal bone disease and implications for osteoporosis.
Osteoporos Int. 1997;7 Suppl 3:S179-83. doi: 10.1007/BF03194368.
本文引用的文献
1
1,25-dihydroxycholecalciferol and 1alpha-hydroxycholecalciferol in hypoparathyroidism.
Lancet. 1974 Jul 6;2(7871):14-7. doi: 10.1016/s0140-6736(74)91348-8.
2
Effects of 1,25-dihydroxycholecalciferol on calcium absorption, muscle weakness, and bone disease in chronic renal failure.
Lancet. 1974 Mar 9;1(7854):379-84. doi: 10.1016/s0140-6736(74)93149-3.
3
Treatment of hypoparathyroidism and pseudohypoparathyroidism with metabolites of vitamin D: evidence for impaired conversion of 25-hydroxyvitamin D to 1 alpha,25-dihydroxyvitamin D.
N Engl J Med. 1975 Oct 23;293(17):840-4. doi: 10.1056/NEJM197510232931702.
4
Variable response to long-term 1alpha-hydroxycholecalciferol in haemodialysis osteodystrophy.
Lancet. 1976 May 22;1(7969):1092-5. doi: 10.1016/s0140-6736(76)90061-1.
Zotero 插件